SCHEMBL2407536

SCHEMBL2407536

O=C(O)c1cncc(-c2cc(Cl)cc([N+](=O)[O-])c2O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.46
TTR P02766 1/20 0.44
ERN1 O75460 3/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
GPR35 Q9HC97 3/20 0.39
FTO Q9C0B1 1/20 0.39
MAPT P10636 4/20 0.38
LMNA P02545 3/20 0.38
POLB P06746 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CASP6 P55212 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NSD2 O96028 1/20 0.37
PLA2G1B P04054 1/20 0.37
PLCG1 P19174 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404933 0.86 TTR (0.48) TTRERN1GPR35MAPTLMNA
SCHEMBL4348393 0.82 ERN1 (0.54) TTRERN1GPR35LMNAPOLB
SCHEMBL29386074 0.82 ERN1 (0.57) TTRERN1MAPTCASP6CRHBP
SCHEMBL2404465 0.82 ERN1 (0.57) TTRERN1MAPTCASP6CRHBP
Niclofolan SCHEMBL1498232 0.76 GPR35 (0.57) TTRGPR35MAPTLMNAPOLB
Niclofolan SCHEMBL29385615 0.76 GPR35 (0.57) TTRGPR35MAPTLMNAPOLB
SCHEMBL2405633 0.75 TTR (0.42) TTRERN1GPR35POLBMEN1
SCHEMBL2406744 0.74 KDM4C (0.46) TTRERN1MAPTLMNAPOLB
SCHEMBL4348195 0.74 CASP6 (0.48) TTRERN1GPR35MAPTLMNA
SCHEMBL2403588 0.74 CA1 (0.50) TTRMAPTLMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-7648971-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. (US) 2010-01-19 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
US-20090176973-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2009-07-09 US disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK HCAR2 1491/4885TTR 199/4885ERN1 4239/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK HCAR2 1491/4885TTR 199/4885ERN1 4239/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK HCAR2 1491/4885TTR 199/4885ERN1 4239/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK HCAR2 1491/4885TTR 199/4885ERN1 4239/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK HCAR2 1491/4885TTR 199/4885ERN1 4239/4885
US-20090176973-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK HCAR2 1491/4885TTR 199/4885ERN1 4239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.